Sign up to save your podcasts
Or
Share Richard S. Finn, MD - How I Think, How I Treat: Remodeling the HCC Treatment Algorithm With New and Emerging Monotherapy, Combination, and Multimodal Approaches
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Richard S. Finn, MD - How I Think, How I Treat: Remodeling the HCC Treatment Algorithm With New and Emerging Monotherapy, Combination, and Multimodal Approaches
Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.
View all episodes
By PVI, PeerView Institute for Medical Education
2.7
33 ratings
Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.
More shows like PeerView Gastroenterology CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners